Read More Pharma Industry News Clarity Pharmaceuticals begins Phase II SECuRE trial with first patient dosed using 67Cu-SAR-bisPSMA and enzalutamide Clarity Pharmaceuticals starts Phase II of SECuRE trial for prostate cancer, combining 67Cu-SAR-bisPSMA with enzalutamide in first treated patient. byPallavi MadhirajuApril 16, 2025